SLXN Overview

SIL204 Development: Silexion Therapeutics has completed toxicology studies for SIL204, a next-generation siRNA therapy targeting mutated KRAS oncogenes in pancreatic cancer, showing no systemic organ toxicity.

Therapeutic Potential: SIL204 has demonstrated significant inhibition of cancer cell growth in preclinical models and positive anti-tumor activity in pancreatic cancer, paving the way for regulatory submissions in Israel and Germany.

Clinical Trial Plans: The therapy is set to progress to a Phase 2/3 trial in Q2 2026, utilizing a unique regimen that combines intratumoral and systemic administration to evaluate safety and efficacy in patients with locally advanced pancreatic cancer.

Stock Performance: Silexion's stock has fluctuated between $2.13 and $63.45 over the past year, closing at $2.44, reflecting a 13.48% increase in recent trading.

Regaining Compliance: Silexion Therapeutics has regained compliance with Nasdaq listing rules regarding minimum bid price and shareholders' equity, confirming a minimum bid price of $1.00 per share and $2.5 million in shareholders' equity.

Clinical Development Focus: The company is advancing towards Phase 2/3 clinical trials for its RNAi therapy SIL204, which has shown promising preclinical results in inhibiting KRAS-driven cancers, and is committed to developing innovative treatments for solid tumor cancers.

Stock Performance: Silexion Therapeutics Corp. (SLXN) stock rose 14.83% to $5.15 on Thursday, with a trading volume significantly higher than its average, following the release of promising preclinical data.

Preclinical Study Findings: New data shows that SIL204 effectively targets pancreatic cancer metastasis, demonstrating anti-tumor activity and significant reductions in tumor burden across multiple organs in a mouse model, supporting its potential for clinical trials.

Stock Performance: Silexion Therapeutics (SLXN) stock surged 188.07% in pre-market trading after positive pre-clinical data for SIL204, which demonstrated effective biodistribution and anti-tumor activity against pancreatic cancer metastasis.

Future Plans: The company plans to initiate Phase 2/3 clinical trials for SIL204 in early 2026, with regulatory submissions expected in late 2025 and early 2026, while analysts maintain a Moderate Buy rating with a target price suggesting a potential 436.12% upside.